vs
RANGE RESOURCES CORP（RRC）とUNITED THERAPEUTICS Corp（UTHR）の財務データ比較。上の社名をクリックして会社を切り替えられます
UNITED THERAPEUTICS Corpの直近四半期売上が大きい（$790.2M vs $786.9M、RANGE RESOURCES CORPの約1.0倍）。UNITED THERAPEUTICS Corpの純利益率が高く（46.1% vs 22.8%、差は23.3%）。RANGE RESOURCES CORPの前年同期比売上増加率が高い（18.0% vs 7.4%）。過去8四半期でRANGE RESOURCES CORPの売上複合成長率が高い（14.6% vs 8.0%）
Range Resources Corporationは米国テキサス州フォートワースに本社を置く天然ガス探鉱・生産企業です。主力事業エリアのマーセラス頁岩層において同地域最大の土地保有者として事業を展開しています。
ユナイテッド・セラピューティクスは米国のバイオテクノロジー企業で、異種移植を含む臓器移植関連の医薬品や技術を開発しています。主力製品の多くは肺疾患治療や臓器製造分野向けで、メリーランド州とノースカロライナ州に2つの本社を置き、米国各地やカナダにも拠点を構えています。
RRC vs UTHR — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $786.9M | $790.2M |
| 純利益 | $179.1M | $364.3M |
| 粗利率 | 94.5% | 86.9% |
| 営業利益率 | — | 45.1% |
| 純利益率 | 22.8% | 46.1% |
| 売上前年比 | 18.0% | 7.4% |
| 純利益前年比 | 88.8% | 20.9% |
| EPS（希薄化後） | $0.75 | $7.66 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $786.9M | $790.2M | ||
| Q3 25 | $655.3M | $799.5M | ||
| Q2 25 | $699.6M | $798.6M | ||
| Q1 25 | $846.3M | $794.4M | ||
| Q4 24 | $667.0M | $735.9M | ||
| Q3 24 | $567.9M | $748.9M | ||
| Q2 24 | $513.2M | $714.9M | ||
| Q1 24 | $598.8M | $677.7M |
| Q4 25 | $179.1M | $364.3M | ||
| Q3 25 | $144.3M | $338.7M | ||
| Q2 25 | $237.6M | $309.5M | ||
| Q1 25 | $97.1M | $322.2M | ||
| Q4 24 | $94.8M | $301.3M | ||
| Q3 24 | $50.7M | $309.1M | ||
| Q2 24 | $28.7M | $278.1M | ||
| Q1 24 | $92.1M | $306.6M |
| Q4 25 | 94.5% | 86.9% | ||
| Q3 25 | 92.5% | 87.4% | ||
| Q2 25 | 95.0% | 89.0% | ||
| Q1 25 | 93.1% | 88.4% | ||
| Q4 24 | 93.7% | 89.7% | ||
| Q3 24 | 94.3% | 88.9% | ||
| Q2 24 | 93.4% | 89.1% | ||
| Q1 24 | 94.7% | 89.2% |
| Q4 25 | — | 45.1% | ||
| Q3 25 | — | 48.6% | ||
| Q2 25 | — | 45.6% | ||
| Q1 25 | — | 48.2% | ||
| Q4 24 | — | 48.6% | ||
| Q3 24 | — | 45.8% | ||
| Q2 24 | — | 44.7% | ||
| Q1 24 | — | 52.6% |
| Q4 25 | 22.8% | 46.1% | ||
| Q3 25 | 22.0% | 42.4% | ||
| Q2 25 | 34.0% | 38.8% | ||
| Q1 25 | 11.5% | 40.6% | ||
| Q4 24 | 14.2% | 40.9% | ||
| Q3 24 | 8.9% | 41.3% | ||
| Q2 24 | 5.6% | 38.9% | ||
| Q1 24 | 15.4% | 45.2% |
| Q4 25 | $0.75 | $7.66 | ||
| Q3 25 | $0.60 | $7.16 | ||
| Q2 25 | $0.99 | $6.41 | ||
| Q1 25 | $0.40 | $6.63 | ||
| Q4 24 | $0.38 | $6.23 | ||
| Q3 24 | $0.21 | $6.39 | ||
| Q2 24 | $0.12 | $5.85 | ||
| Q1 24 | $0.38 | $6.17 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $204.0K | $2.9B |
| 総負債低いほど良い | $1.2B | — |
| 株主資本純資産 | $4.3B | $7.1B |
| 総資産 | $7.4B | $7.9B |
| 負債/資本比率低いほどレバレッジが低い | 0.28× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $204.0K | $2.9B | ||
| Q3 25 | $175.0K | $2.8B | ||
| Q2 25 | $134.0K | $3.0B | ||
| Q1 25 | $344.6M | $3.3B | ||
| Q4 24 | $304.5M | $3.3B | ||
| Q3 24 | $277.4M | $3.3B | ||
| Q2 24 | $251.1M | $3.0B | ||
| Q1 24 | $343.1M | $2.7B |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.7B | — | ||
| Q4 24 | $1.7B | — | ||
| Q3 24 | $1.7B | — | ||
| Q2 24 | $1.7B | — | ||
| Q1 24 | $1.8B | — |
| Q4 25 | $4.3B | $7.1B | ||
| Q3 25 | $4.2B | $6.6B | ||
| Q2 25 | $4.1B | $7.2B | ||
| Q1 25 | $3.9B | $6.8B | ||
| Q4 24 | $3.9B | $6.4B | ||
| Q3 24 | $3.9B | $6.1B | ||
| Q2 24 | $3.9B | $5.7B | ||
| Q1 24 | $3.8B | $5.3B |
| Q4 25 | $7.4B | $7.9B | ||
| Q3 25 | $7.2B | $7.4B | ||
| Q2 25 | $7.1B | $7.9B | ||
| Q1 25 | $7.4B | $7.7B | ||
| Q4 24 | $7.3B | $7.4B | ||
| Q3 24 | $7.2B | $7.1B | ||
| Q2 24 | $7.3B | $6.7B | ||
| Q1 24 | $7.4B | $6.5B |
| Q4 25 | 0.28× | — | ||
| Q3 25 | 0.29× | — | ||
| Q2 25 | 0.29× | — | ||
| Q1 25 | 0.43× | — | ||
| Q4 24 | 0.43× | — | ||
| Q3 24 | 0.44× | — | ||
| Q2 24 | 0.44× | — | ||
| Q1 24 | 0.46× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $257.5M | $346.2M |
| フリーキャッシュフロー営業CF - 設備投資 | — | $173.3M |
| FCFマージンFCF / 売上 | — | 21.9% |
| 設備投資強度設備投資 / 売上 | — | 21.9% |
| キャッシュ転換率営業CF / 純利益 | 1.44× | 0.95× |
| 直近12ヶ月FCF直近4四半期 | — | $1.0B |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $257.5M | $346.2M | ||
| Q3 25 | $247.5M | $562.1M | ||
| Q2 25 | $336.2M | $191.7M | ||
| Q1 25 | $330.1M | $461.2M | ||
| Q4 24 | $217.9M | $341.2M | ||
| Q3 24 | $245.9M | $377.2M | ||
| Q2 24 | $148.8M | $232.2M | ||
| Q1 24 | $331.9M | $376.5M |
| Q4 25 | — | $173.3M | ||
| Q3 25 | — | $351.6M | ||
| Q2 25 | — | $129.5M | ||
| Q1 25 | — | $386.3M | ||
| Q4 24 | — | $254.5M | ||
| Q3 24 | — | $300.7M | ||
| Q2 24 | — | $187.1M | ||
| Q1 24 | — | $338.3M |
| Q4 25 | — | 21.9% | ||
| Q3 25 | — | 44.0% | ||
| Q2 25 | — | 16.2% | ||
| Q1 25 | — | 48.6% | ||
| Q4 24 | — | 34.6% | ||
| Q3 24 | — | 40.2% | ||
| Q2 24 | — | 26.2% | ||
| Q1 24 | — | 49.9% |
| Q4 25 | — | 21.9% | ||
| Q3 25 | — | 26.3% | ||
| Q2 25 | — | 7.8% | ||
| Q1 25 | — | 9.4% | ||
| Q4 24 | — | 11.8% | ||
| Q3 24 | — | 10.2% | ||
| Q2 24 | — | 6.3% | ||
| Q1 24 | — | 5.6% |
| Q4 25 | 1.44× | 0.95× | ||
| Q3 25 | 1.72× | 1.66× | ||
| Q2 25 | 1.42× | 0.62× | ||
| Q1 25 | 3.40× | 1.43× | ||
| Q4 24 | 2.30× | 1.13× | ||
| Q3 24 | 4.85× | 1.22× | ||
| Q2 24 | 5.18× | 0.83× | ||
| Q1 24 | 3.60× | 1.23× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
RRC
| Natural Gas Natural Gas Liquids And Oil Sales | $745.5M | 95% |
| Brokered Natural Gas And Marketing | $41.3M | 5% |
UTHR
| Tyvaso DPI | $338.6M | 43% |
| Remodulin | $128.0M | 16% |
| Nebulized Tyvaso | $125.7M | 16% |
| Orenitram | $121.2M | 15% |
| Unituxin | $62.3M | 8% |
| Adcirca | $7.8M | 1% |
| Other | $6.6M | 1% |
